The abstract is read at the publisher; the summary is JClub's.
In 10 patients with unresectable or metastatic, treatment-refractory pheochromocytoma or paraganglioma, a single 2.1 MBq/kg dose of 211At-MABG showed no dose-limiting toxicities.
- Why it matters: Current 131I-MIBG therapy is constrained by low complete response rates and prolonged radiation isolation, motivating safer, more effective radiopharmaceutical options.
- What they did: This first-in-human, open-label, single-arm phase I study used a 3+3 dose-escalation (0.65, 1.3, 2.1 MBq/kg) and measured safety, pharmacokinetics, and tumor response after one intravenous dose.
- The result: Cumulative urinary excretion reached 65% within 72 hours, and during up to 12 weeks there were 1 partial response, 7 stable disease, and 2 progressive disease, supporting clinical feasibility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.